Mahmut I Yilmaz1, Erkan Demirkaya2, Cengizhan Acikel1, Mehmet Saldir1, Servet Akar1, Tuncer Cayci1, Mutlu Saglam1, Hilmi U Unal1, Mahmut Gok1, Adem Polat3, Hakkı Cetinkaya1, Tayfun Eyileten1, Sebahattin Sari1, Ali O Yildirim1, Alper Sonmez1, Yusuf Oguz1, Abdulgaffar Vural1, Seza Ozen1, Juan Jesús Carrero3. 1. Department of Nephrology, Department of Pediatric Rheumatology, Gülhane School of Medicine, FMF Arthritis Vasculitis and Orphan Disease Research Center, Institute of Health Sciences, R&D Center, Ankara, Department of Rheumatology, Eylül University, Izmir, Department of Biochemistry, Department of Radiology, Department of Endocrinology, Gülhane School of Medicine, Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Center for Molecular Medicine and Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden. 2. Department of Nephrology, Department of Pediatric Rheumatology, Gülhane School of Medicine, FMF Arthritis Vasculitis and Orphan Disease Research Center, Institute of Health Sciences, R&D Center, Ankara, Department of Rheumatology, Eylül University, Izmir, Department of Biochemistry, Department of Radiology, Department of Endocrinology, Gülhane School of Medicine, Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Center for Molecular Medicine and Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden. Department of Nephrology, Department of Pediatric Rheumatology, Gülhane School of Medicine, FMF Arthritis Vasculitis and Orphan Disease Research Center, Institute of Health Sciences, R&D Center, Ankara, Department of Rheumatology, Eylül University, Izmir, Department of Biochemistry, Department of Radiology, Department of Endocrinology, Gülhane School of Medicine, Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Center for Molecular Medicine and Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden. erkandemirkaya@yahoo.com. 3. Department of Nephrology, Department of Pediatric Rheumatology, Gülhane School of Medicine, FMF Arthritis Vasculitis and Orphan Disease Research Center, Institute of Health Sciences, R&D Center, Ankara, Department of Rheumatology, Eylül University, Izmir, Department of Biochemistry, Department of Radiology, Department of Endocrinology, Gülhane School of Medicine, Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Center for Molecular Medicine and Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden. Department of Nephrology, Department of Pediatric Rheumatology, Gülhane School of Medicine, FMF Arthritis Vasculitis and Orphan Disease Research Center, Institute of Health Sciences, R&D Center, Ankara, Department of Rheumatology, Eylül University, Izmir, Department of Biochemistry, Department of Radiology, Department of Endocrinology, Gülhane School of Medicine, Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Center for Molecular Medicine and Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden.
Abstract
OBJECTIVES: Secondary amyloidosis is the most important complication of FMF and endothelial function is more severely impaired. Elevated asymmetric dimethyl arginine (ADMA) may mediate the excess cardiovascular disease (CVD) risk of this group. We aimed to compare endothelial function characteristics, including ADMA, in patients with FMF-related amyloidosis and primary glomerulopathies and to define risk factors for a CVD event. METHODS: We undertook a cross-sectional study with prospective follow-up including consecutive patients with FMF-related amyloidosis (n = 98) or other non-diabetic glomerulopathies (n = 102). All patients had nephrotic-range proteinuria and normal glomerular filtration rate. Flow-mediated dilatation (FMD) was assessed and ADMA levels, CRP and pentraxin 3 (PTX3) were determined. Patients were followed for cardiovascular events. RESULTS: Amyloidosis patients secondary to FMF showed higher levels of ADMA, CRP and PTX3 and lower FMD as compared with patients with other glomerulopathies. Cardiovascular events (n = 54) were registered during 3 years of follow-up. Increased ADMA levels and lower FMD were observed in patients with cardiovascular risk in both groups, but especially in individuals with amyloidosis. CONCLUSION: Patients with FMF-related amyloidosis have increased CVD event risk, probably related to the high ADMA levels, elevated inflammatory markers and decreased FMD measures observed in these patients.
OBJECTIVES: Secondary amyloidosis is the most important complication of FMF and endothelial function is more severely impaired. Elevated asymmetric dimethyl arginine (ADMA) may mediate the excess cardiovascular disease (CVD) risk of this group. We aimed to compare endothelial function characteristics, including ADMA, in patients with FMF-related amyloidosis and primary glomerulopathies and to define risk factors for a CVD event. METHODS: We undertook a cross-sectional study with prospective follow-up including consecutive patients with FMF-related amyloidosis (n = 98) or other non-diabetic glomerulopathies (n = 102). All patients had nephrotic-range proteinuria and normal glomerular filtration rate. Flow-mediated dilatation (FMD) was assessed and ADMA levels, CRP and pentraxin 3 (PTX3) were determined. Patients were followed for cardiovascular events. RESULTS:Amyloidosispatients secondary to FMF showed higher levels of ADMA, CRP and PTX3 and lower FMD as compared with patients with other glomerulopathies. Cardiovascular events (n = 54) were registered during 3 years of follow-up. Increased ADMA levels and lower FMD were observed in patients with cardiovascular risk in both groups, but especially in individuals with amyloidosis. CONCLUSION:Patients with FMF-related amyloidosis have increased CVD event risk, probably related to the high ADMA levels, elevated inflammatory markers and decreased FMD measures observed in these patients.
Authors: Murat Yuksel; Abdulkadir Yildiz; Mustafa Oylumlu; Fatih Mehmet Turkcu; Mehmet Zihni Bilik; Aysun Ekinci; Bilal Elbey; Ebru Tekbas; Sait Alan Journal: Clin Rheumatol Date: 2015-03-07 Impact factor: 2.980
Authors: Veysel Ozalper; Muammer Kara; Alpaslan Tanoglu; Ibrahim Cetındaglı; Coskun Ozturker; Yusuf Hancerlı; Serdar Hıra; Kemal Kara; Yavuz Beyazıt; Yusuf Yazgan Journal: Clin Rheumatol Date: 2017-01-10 Impact factor: 2.980
Authors: Micol Romano; David Piskin; Roberta A Berard; Bradley C Jackson; Cengizhan Acikel; Juan J Carrero; Helen J Lachmann; Mahmut I Yilmaz; Erkan Demirkaya Journal: Sci Rep Date: 2020-10-27 Impact factor: 4.379